• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Aclaris Therapeutics Inc.

    5/15/25 10:45:24 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Aclaris Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, $0.00001 par value

    (Title of Class of Securities)


    00461U105

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    00461U105


    1Names of Reporting Persons

    Rock Springs Capital Management LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,046,309.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,046,309.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,046,309.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.7 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    00461U105


    1Names of Reporting Persons

    Rock Springs Capital LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,046,309.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,046,309.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,046,309.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.7 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    00461U105


    1Names of Reporting Persons

    Rock Springs Capital Master Fund LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    00461U105


    1Names of Reporting Persons

    Mark Bussard
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,046,309.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,046,309.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,046,309.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.7 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    00461U105


    1Names of Reporting Persons

    Kris Jenner
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,046,309.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,046,309.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,046,309.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.7 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Aclaris Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    701 LEE ROAD, SUITE 103, WAYNE, PA, 19087
    Item 2. 
    (a)Name of person filing:

    This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"): i. Rock Springs Capital Management LP ("RSCM"); ii. Rock Springs Capital LLC ("RSC"); iii. Rock Springs Capital Master Fund LP ("Master Fund"); iv. Mark Bussard; and v. Kris Jenner This Statement relates to the shares of Common Stock (the "Shares") held directly by the Master Fund, which is a Cayman Island exempted limited partnership, and Four Pines Master Fund LP ("Four Pines"), which is a Cayman Islands exempted limited partnership, and indirectly held by RSCM, a Delaware limited partnership, and RSC, a Delaware limited liability company. RSCM serves as the investment manager to each of the Master Fund and Four Pines. RSC is the general partner of RSCM. Mark Bussard and Kris Jenner each own 50% of the management company.
    (b)Address or principal business office or, if none, residence:

    Rock Springs Capital Management LP, Rock Springs Capital LLC, Rock Springs Capital Master Fund LP; Mark Bussard, and Kris Jenner: 650 South Exeter, Suite 1070 Baltimore, MD 21202
    (c)Citizenship:

    Rock Springs Capital Management LP - Delaware; Rock Springs Capital LLC - Delaware; Rock Springs Capital Master Fund LP - Cayman Islands; Mark Bussard - United States; Kris Jenner - United States
    (d)Title of class of securities:

    Common Stock, $0.00001 par value
    (e)CUSIP No.:

    00461U105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    5,046,309
    (b)Percent of class:

    4.7  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    5,046,309

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    5,046,309 The percent of class is determined by dividing the number of Shares beneficially owned by the Reporting Persons by 107,918,821, as reported on the Issuer's 10-K filed on February 27, 2025.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See disclosure in Items 2 and 4 hereof. Certain funds listed in Item 2(a) are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares covered by this Statement that may be deemed to be beneficially owned by the Reporting Persons.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Please see response to Item 2.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Rock Springs Capital Management LP
     
    Signature:/s/ Mark Bussard
    Name/Title:Mark Bussard - Member
    Date:05/15/2025
     
    Rock Springs Capital LLC
     
    Signature:/s/ Mark Bussard
    Name/Title:Mark Bussard - Member
    Date:05/15/2025
     
    Rock Springs Capital Master Fund LP
     
    Signature:/s/ Mark Bussard
    Name/Title:Mark Bussard - Member
    Date:05/15/2025
     
    Mark Bussard
     
    Signature:/s/ Mark Bussard
    Name/Title:Mark Bussard
    Date:05/15/2025
     
    Kris Jenner
     
    Signature:/s/ Kris Jenner
    Name/Title:Kris Jenner
    Date:05/15/2025
    Exhibit Information

    JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Date: May 15, 2025 Rock Springs Capital Management LP By: Rock Springs Capital LLC, General Partner By: Mark Bussard Name: Mark Bussard Title: Member Rock Springs Capital LLC By: Mark Bussard Name: Mark Bussard Title: Member Rock Springs Capital Master Fund LP By: Rock Springs Capital Management LP, Investment Manager By: Rock Springs Capital LLC, General Partner By: Mark Bussard Name: Mark Bussard Title: Member Mark Bussard By: Mark Bussard Name: Mark Bussard Kris Jenner By: Kris Jenner Name: Kris Jenner

    Get the next $ACRS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRS

    DatePrice TargetRatingAnalyst
    7/10/2025$6.00Overweight
    Piper Sandler
    5/28/2025$8.00Outperform
    Wedbush
    3/18/2025Overweight
    Cantor Fitzgerald
    12/23/2024$20.00Neutral → Buy
    H.C. Wainwright
    11/20/2024Neutral → Overweight
    Cantor Fitzgerald
    11/19/2024$2.00 → $7.00Market Perform → Outperform
    Leerink Partners
    11/19/2024$8.00Neutral → Buy
    BTIG Research
    11/19/2024$2.00 → $7.00Hold → Buy
    Jefferies
    More analyst ratings

    $ACRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler resumed coverage on Aclaris Therapeutics with a new price target

    Piper Sandler resumed coverage of Aclaris Therapeutics with a rating of Overweight and set a new price target of $6.00

    7/10/25 8:47:17 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush initiated coverage on Aclaris Therapeutics with a new price target

    Wedbush initiated coverage of Aclaris Therapeutics with a rating of Outperform and set a new price target of $8.00

    5/28/25 8:54:54 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Aclaris Therapeutics

    Cantor Fitzgerald resumed coverage of Aclaris Therapeutics with a rating of Overweight

    3/18/25 8:23:58 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mehra Anand bought $1,499,998 worth of shares (666,666 units at $2.25), increasing direct ownership by 1,537% to 710,030 units (SEC Form 4)

    4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

    11/20/24 4:20:04 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Leonard Braden Michael bought $472,757 worth of shares (373,569 units at $1.27) (SEC Form 4)

    4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

    8/5/24 3:57:34 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Leonard Braden Michael bought $359,010 worth of shares (273,730 units at $1.31) (SEC Form 4)

    4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

    7/31/24 4:10:09 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ACRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SEC Form 4 filed by Chief Scientific Officer Kolbeck Roland Wilhelm

    4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

    8/5/25 4:33:44 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Kolbeck Roland Wilhelm

    3 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

    8/5/25 4:31:31 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Milano Vincent converted options into 4,793 shares, increasing direct ownership by 38% to 17,316 units (SEC Form 4)

    4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

    6/9/25 4:20:29 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    - Positive Clinical Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Confirm Tolerability Profile, Show Strong Efficacy Signal, and Validate ITK as Therapeutic Target - - Advanced Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) into Phase 2 Trial in Atopic Dermatitis (AD); Patient Dosing Underway - - Initiated Dosing in Phase 1a/1b Clinical Program for Anti-TSLP/IL-4R Bispecific Antibody ATI-052 - - Strong Cash Runway Expected to Fund Operations into the Second Half of 2028 - WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory

    8/7/25 6:59:32 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

    - Primary Endpoint Analysis Confirms Favorable Tolerability Profile of ATI-2138 Without Certain Risks Associated with Other Agents in the Class - - Efficacy Results Show Comparable Outcomes to Approved Therapies with Potential for Improved Tolerability, Supporting Exploration of Higher Doses in Future Clinical Trials - - Pharmacodynamic Results Validate Therapeutic Potential of ITK Inhibition and Corroborate Potential of Aclaris' ITK Franchise - - Management to Host a Conference Call to Discuss Results Today at 5:00PM EDT - WAYNE, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel pro

    7/29/25 4:01:47 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclaris Therapeutics Announces Leadership Transition

    - Roland Kolbeck, Ph.D. Appointed as Chief Scientific Officer - - Joe Monahan, Ph.D. will Continue to Support Aclaris as Special Scientific Advisor to the Chief Executive Officer through March 2026 as Part of Planned Retirement - WAYNE, Pa., July 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Roland Kolbeck, Ph.D. has been appointed as Chief Scientific Officer, replacing Joe Monahan, Ph.D. who will remain with the Company as Special Scientific Advisor to the Chief Executive Officer through the first quarter of 2026 as

    7/28/25 8:45:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    SEC Filings

    View All

    SEC Form 10-Q filed by Aclaris Therapeutics Inc.

    10-Q - Aclaris Therapeutics, Inc. (0001557746) (Filer)

    8/7/25 4:31:13 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclaris Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)

    8/7/25 7:15:40 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclaris Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)

    7/29/25 4:15:18 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/25/24 11:02:19 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/22/24 4:00:23 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/21/24 4:51:50 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    Leadership Updates

    Live Leadership Updates

    View All

    Aclaris Therapeutics Announces Leadership Transition

    - Roland Kolbeck, Ph.D. Appointed as Chief Scientific Officer - - Joe Monahan, Ph.D. will Continue to Support Aclaris as Special Scientific Advisor to the Chief Executive Officer through March 2026 as Part of Planned Retirement - WAYNE, Pa., July 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Roland Kolbeck, Ph.D. has been appointed as Chief Scientific Officer, replacing Joe Monahan, Ph.D. who will remain with the Company as Special Scientific Advisor to the Chief Executive Officer through the first quarter of 2026 as

    7/28/25 8:45:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

    WAYNE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Jesse Hall, M.D. has been appointed as Chief Medical Officer. Dr. Hall's extensive medical and clinical development experience in areas including immunology and antibody development will be essential as he leads Aclaris' clinical strategy to fully leverage the opportunities in the Company's portfolio of immuno-inflammatory product candidates. "At Aclaris, our vision is to drive the leading edge of therapeutic innovation in I&I; Jesse shares this vision and

    4/29/25 7:00:32 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

    CAMBRIDGE, Mass., April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately. Dr. Manion brings over two decades of experience in pharmaceutical research and development, having held leadership roles across several biotechnology and pharmaceutical companies. He succeeds interim CEO Abbie Celniker, Ph.D., a partner at Third Rock Ventures, who will continue to serve as Chair of the Company's Board of Directors.

    4/23/24 8:00:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    Financials

    Live finance-specific insights

    View All

    Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    - Positive Clinical Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Confirm Tolerability Profile, Show Strong Efficacy Signal, and Validate ITK as Therapeutic Target - - Advanced Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) into Phase 2 Trial in Atopic Dermatitis (AD); Patient Dosing Underway - - Initiated Dosing in Phase 1a/1b Clinical Program for Anti-TSLP/IL-4R Bispecific Antibody ATI-052 - - Strong Cash Runway Expected to Fund Operations into the Second Half of 2028 - WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory

    8/7/25 6:59:32 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

    - Primary Endpoint Analysis Confirms Favorable Tolerability Profile of ATI-2138 Without Certain Risks Associated with Other Agents in the Class - - Efficacy Results Show Comparable Outcomes to Approved Therapies with Potential for Improved Tolerability, Supporting Exploration of Higher Doses in Future Clinical Trials - - Pharmacodynamic Results Validate Therapeutic Potential of ITK Inhibition and Corroborate Potential of Aclaris' ITK Franchise - - Management to Host a Conference Call to Discuss Results Today at 5:00PM EDT - WAYNE, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel pro

    7/29/25 4:01:47 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

    - Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese Partner CTTQ Provide Clinical Evidence of Enhanced Potency of Bosakitug (ATI-045) and Opportunity for Development Partnerships - - Investigational New Drug (IND) Application for Bispecific Antibody ATI-052 Cleared by U.S. Food and Drug Administration - WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial res

    5/8/25 6:50:51 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care